BioMarin (BMRN) announced Monday the discontinuation of three Voxzogo Phase 2 studies in Turner Syndrome, SHOX-difficiency, and ACAN-difficiency, due to several cases of Slipped Capital Femoral Epiphysis in investigator-sponsored trials, Wells Fargo tells investors in a research note. The firm, which has an Overweight rating and $75 price target on the shares, views the SCFE risk as more indication-specific than target-driven, and views the BioMarin story as less dependent on Voxzogo going forward. Wells is a buyer on any weakness.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials
- BioMarin discontinues enrollment in some Phase 2 Voxzogo trials
- BioMarin’s Voxzogo shows impact in pediatric achondroplasia
- BioMarin: Strategic Amicus Acquisition Supports Buy Rating Despite Voxzogo Assumption Reset
- BioMarin price target lowered to $85 from $97 at BofA